Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-674-2 | CAS number: 147993-65-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Sensitisation data (human)
Administrative data
- Endpoint:
- sensitisation data (humans)
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Meets generally accepted scientific standards, well documented and acceptable for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- The low prevalence of occupational asthma and antibody-dependent sensitization to diphenylmethane diisocyanate in a plant engineered for minimal exposure to diisocyanates
- Author:
- Bernstein DI, Korbee L, Stauder T, Bernstein JA, Scinto J, Herd ZL, Bernstein IL.
- Year:
- 1 993
- Bibliographic source:
- J. Allergy Clin. Immunol..; 92: 387-396
Materials and methods
- Type of sensitisation studied:
- respiratory
- Study type:
- other: cross-sectional study
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- In a cross-sectional study, 243 workers exposed to MDI were screened for occupational asthma and antibody-dependent sensitization to MDI. Methods included a questionnaire, immunologic tests and measurements of peak expiratory flow rate.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 9016-87-9
- Cas Number:
- 9016-87-9
- IUPAC Name:
- 9016-87-9
- Reference substance name:
- Isocyanic acid, polymethylenepolyphenylene ester
- IUPAC Name:
- Isocyanic acid, polymethylenepolyphenylene ester
- Reference substance name:
- Isocyanic acid, polymethylenepolyphenylene ester
- Cas Number:
- 9016-87-9
- Molecular formula:
- Unspecified
- IUPAC Name:
- Isocyanic acid, polymethylenepolyphenylene ester
- Test material form:
- aerosol dispenser: not specified
- Remarks:
- migrated information: aerosol
Constituent 1
Constituent 2
Constituent 3
Method
- Type of population:
- occupational
- Ethical approval:
- not specified
- Subjects:
- - Number of subjects exposed: 243
- Sex: men (175) and women (68)
- Duration of employment: 0-32 months with an average of 18.2 months
- Occupation: workers in the urethane mould lines (147), worker in administrative/transport/maintenance jobs (96)
Of note, from 1992 to 1992, 41 (17%) of the 243 employees left the mould area; only 4 (1.6%) were transferred for work-related medical reasons. - Route of administration:
- inhalation
- Details on study design:
- TYPE AND DETAILS OF TESTS USED
- Questionnaire
A questionnaire was taken by an interviewer, so as to reveal upper and lower respiratory symptoms, their time of onset, and their resolution or persistence after leaving the workplace. Questions elicited data pertaining to possible risk factors such as smoking and a personal history of seasonal respiratory symptoms during the spring, summer, and late fall. Questionnaire-derived diagnoses were assigned to each worker that included (1) probable or possible OA, (2) lower respiratory irritant responses; (3) non-OA, (4) urticaria or skin rash; (5) chronic bronchitis (nonoccupational); (6) occupational nasal symptoms and (7) nonoccupational nasal symptoms.
- Immunological tests
Sera from workers were assessedfor specific IgG and IgE antibodies to MDI-HSA.
- Lung function measurements
All workers who reported at least one lower respiratory symptom of wheezing, coough or shortness of breath and those workers with MDI-HSA specific antibodies were instructed to perform serial peak expiratory flow rate (PEFR) sstudies.
In all workers with PEFR variability, a detailed medical evaluation by a physician experienced in the evaluation of OA was done.
Under a casecontrol design, serial PEFR studies were also conducted on 23 randomly selected workers who did not report lower respiratory symptoms on the questionnaire.
Results and discussion
- Results of examinations:
- EXPOSURE MEASUREMENTS
During the entire 3 years that the plant had been in operation short-term exposure did not exceed the accepted threshold limit value of 0.005 ppm.
QUESTIONNAIRE DIAGNOSES
9 (4%) workers had diagnoses of possible OA, 26 (11%) had lower respiratory irritant symptoms; 4 (2%) had diagnoses of non-OA, 2 (1%) reported chronic bronchitis; work-related urticaria and angioedema were found in 2 (1%); 88 (36%) reported work-related nasal symptoms; 22 (9%) reported non-work-related nasal symptoms; and, finally, 111 (46%) workers reported no symptoms at all.
Overall, work-related lower respiratory symptoms (OA and lower respiratory irritant) were reported by 15% of 243 workers.
No significant associations were found between these diagnoses and the presence or absence of risk factors including smoking, atopic history and job description. Equally, there was no significant association with duration of exposure.
IMMUNOLOGIC STUDIES
Of the 243 workers tested, only 2 had elevated levels of both serum specific IgE and IgG to MDI-HSA.
PEFR STUDIES
PEFR studies were performed in 43 workers who reported lower respiratory symptoms and in 23 workers free of symptoms who were randomly selected to serve as case controls. Of nine workers with questionnaire diagnoses of OA, three exhibited work-related PEFR variability, whereas two of four with non-OA exhibited non-work-related variability. Significant PEFR variability was not detected in workers classified with lower respiratory irritant symptoms. Interestingly, 2 of 23 of the “asymptomatic” case control subjects exhibited significant variability in PEFR. A significant association was found between questionnaire-derived diagnoses of asthma (occupational or non-occupational) and the presence of PERF variability.
Applicant's summary and conclusion
- Conclusions:
- Strict control and monitoring of ambient MDI exposure was associated with a low prevalence of specific sensitization to MDI and a lower than expected prevalence of occupational asthma.
- Executive summary:
This paper by Bernstein et al. (1993) described a cross-sectional study of 243 workers exposed to diphenylmethane diisocyanate (MDI) in a urethane mold plant that had been designed to minimize MDI exposure (levels were maintained below 0.005 ppm and were continuously monitored).
All participants were screened by questionnaire and tests for serum antibodies to MDI-human serum albumin (HSA). On the basis of questionnaire responses, diagnoses were derived that included occupational asthma (OA), non-OA, work-related and non-work-related rhinitis and lower respiratory irritant responses. Serial peak respiratory flow rate studies were performed for 2 weeks in 43 workers with and in 23 workers without lower respiratory symptoms.
Results of serial peak expiratory flow rate studies were abnormal in 3 (33%) of 9 workers with OA, in 2 (50%) of 4 with non-OA and in 2 (9%) of 23 case control subjects. A significant association was found between peak flow rate variability and a questionnaire asthma diagnosis. Physicians confirmed three cases of OA, one of which occurred in a control worker who was free of symptoms. In all three cases asthma symptoms remitted after the worker left the workplace. Serum specific IgE and IgG levels were elevated in 2 of 243 workers.
On the basis of these cases, specific work activities associated with exposure to MDI were identified and corrective measures were instituted. Strict control and monitoring of ambient MDI exposure was associated with a low prevalence of specific sensitization to MDI and a lower than expected prevalence of OA.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
